Neoleukin Therapeutics appoints first general counsel
Seattle-based Neoleukin Therapeutics has hired Holly Vance as general counsel. She is the first person to hold that position with the company, according to a spokesperson.
Vance was previously at the Bill & Melinda Gates Foundation, where she was associate general counsel and provided legal and strategic advice on investments and transactions to the foundation’s Strategic Investment Fund with a focus on the life sciences sector.
Before her time at the Gates Foundation, Vance was a partner in the Seattle office of law firm K&L Gates, practicing corporate and securities law.
Nasdaq-listed Neoleukin is a biopharmaceutical company creating new immunotherapies for cancer, inflammation and autoimmunity using protein design technology.
‘Holly brings a wealth of legal experience across a wide range of corporate and transactional matters to Neoleukin. Her leadership role at the Gates Foundation Strategic Investment Fund combined with her scientific and healthcare background will be invaluable to the company, and we are very excited to have her join our leadership team,’ says Neoleukin CEO Jonathan Drachman in a statement.
‘I’m pleased to join Neoleukin at this exciting time and look forward to being actively involved in the company’s strategic initiatives,’ Vance adds.